Erratum to: Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months (Digestive Diseases and Sciences, (2017), 62, 5, (1305-1312), 10.1007/s10620-017-4511-4);Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months

Digestive Diseases and Sciences

Volumn 62, Issue 5, 2017, Pages 1305-1312

  Arguelles Arias F ^a   Guerra Veloz, M F ^a   Perea Amarillo, R ^a   Vilches Arenas, A ^a   Castro Laria, L ^a   Maldonado Perez B ^a   Chaaro, D ^a   Benitez Roldan A ^a   Merino, V ^a   Ramirez G ^a   Caunedo Alvarez A ^a   Romero Gomez M ^a,b  

^a HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Biosimilar agent; Crohn s disease; CT P13; Infliximab; Ulcerative colitis

Indexed keywords

BIOSIMILAR AGENT; CT P 13; INFLIXIMAB; UNCLASSIFIED DRUG; CT-P13; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ADULT; ARTHRALGIA; ARTICLE; CROHN DISEASE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PARESTHESIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; SKIN MANIFESTATION; TREATMENT RESPONSE; ULCERATIVE COLITIS; DRUG ADMINISTRATION; INFLAMMATORY BOWEL DISEASES; MIDDLE AGED;

ADULT; ANTIBODIES, MONOCLONAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REMISSION INDUCTION;

EID: 85014667283     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-017-4657-0     Document Type: Erratum

References (33)

1. Papadakis KA, Targan SR. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med. 2000;51:289–298.
2. Côté-Daigneault J, Bouin M, Lahaie R, Colombel J-F, Poitras P. Biologics in inflammatory bowel disease: what are the data? U Eur Gastroenterol J. 2015;3:419–428.
3. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117:244–279.
4. European Medicines Agency—European public assessment reports—Infliximab. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d124&source=homeMedSearch&keyword=infliximab&category=human&isNewQuery=true.
5. European Medicines Agency—European public assessment reports—Adalimumab. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=%0AWC0b01ac058001d124&source=homeMedSearch&keyword=adalimumab&category=human&isNewQuery=true.
6. European Medicines Agency—European public assessment reports—Simponi (golimumab). http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000992/human_med_001053.jsp&mid=WC0b01ac058001d124.
7. Bodger K, Kikuchi T, Hughes D. Cost-effectiveness of biological therapy for Crohn’s disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. Aliment Pharmacol Ther. 2009;30:265–274.
8. World Health Organization. Expert Committee on biological standarization. Geneva, 19–23 Oct 2009. Guidelines on evaluation of similar biotherapeutic products (SBPs). http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf.
9. Haustein R, de Millas C, Höer A, Häyssker B. Saving money in the European healthcare systems with biosimilars. GaBI J. 2012;1:120–126.
10. Kim J, An Hong J, Kudrin A. P137 5 year budget impact analysis of CT-P13 (Infliximab) for the treatment of Crohn’s disease in UK, Italy and France. https://www.ecco-ibd.eu/index.php/publications/congress-abstract-s/abstracts-2015/item/p137-5-year-budget-impact-analysis-of-ct-p13-infliximab-for-the-treatment-of-crohnaposs-disease-in-uk-italy-and-france.html.
11. European Medicines Agency. Committee for medicinal products for human use (CHMP). Assessment report: Remsima (infliximab). 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002576/WC500151486.pdf.
12. ®. MAbs. 2014;6:1163–1177.
13. Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72:1613–1620.
14. Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72:1605–1612.
15. Goll GL, Olsen IC, Jorgensen KK, et al. Biosimilar infliximab (CT-P13) is not inferior to originator infliximab: results from a 52-week randomized switch trial in Norway. 2016 ACR/ARHP annual meeting. Abstract 19L. http://acrabstracts.org/abstract/biosimilar-infliximab-ct-p13-is-not-inferior-to-originator-infliximab-results-from-a-52-week-randomized-switch-trial-in-norway/.
16. Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 in Patients With Active Crohn’s Disease—Full Text View—ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02096861.
17. To Evaluate the Safety and Efficacy of Remsima™ in Patients With Crohn’s Disease (CD) or Ulcerative Colitis (UC)—Full Text View—ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02326155.
18. EPAR summary for the public. Remsima, INN-infliximab. 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002576/WC500150872.pdf.
19. Clinical Addendum PREA. Biosimilar CT-P13. Food and Drug Administration. 2016. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM510208.pdf.
20. Kern Pharma Biologics lanza su primer biosimilar en España: Remsima. 2015. http://www.pmfarma.es/noticias/20238-kern-pharma-biologics-lanza-su-primer-biosimilar-en-espana-remsima.html.
21. Ficha técnica de Remsima, INN—infliximab. http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/002576/WC500150871.pdf.
22. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19:5–36.
23. Best WR. Predicting the Crohn’s disease activity index from the Harvey-Bradshaw Index. Inflamm Bowel Dis. 2006;12:304–310.
24. Dignass A, Eliakim R, Magro F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis. 2012;6:965–990.
25. Unanticipated Problems Involving Risks & Adverse Events Guidance (2007). HHS.gov. Office for Human Research Protections. http://www.hhs.gov/ohrp/regulations-and-policy/guidance/reviewing-unanticipated-problems/index.html.
26. Jahnsen J, Detlie TE, Vatn S, Ricanek P. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: a Norwegian observational study. Expert Rev Gastroenterol Hepatol. 2015;9:45–52.
27. Jung YS, Park DI, Kim YH, et al. Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: a retrospective multicenter study. J Gastroenterol Hepatol. 2015;30:1705–1712.
28. Farkas K, Rutka M, Bálint A, et al. Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn’s disease and ulcerative colitis—experiences from a single center. Expert Opin Biol Ther. 2015;15:1257–1262.
29. Keil R, Wasserbauer M, Zádorová Z, et al. Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn’s disease and ulcerative colitis. Scand J Gastroenterol. 2016;51:1062–1068.
30. ® to the biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational Cohort study. J Crohns Colitis. 2016;10:1287–1293.
31. Park SH, Kim Y-H, Lee JH, et al. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea. Expert Rev Gastroenterol Hepatol. 2015;9:35–44.
32. Reinisch W, Louis E, Danese S. The scientific and regulatory rationale for indication extrapolation: a case study based on the infliximab biosimilar CT-P13. Expert Rev Gastroenterol Hepatol. 2015;9:17–26.
33. Ben-Horin S, Heap GA, Ahmad T, et al. The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications? Expert Rev Gastroenterol Hepatol. 2015;9:27–34.